Trip6 is a member of a subfamily of LIM domain proteins, including also zyxin, LPP, Ajuba, and Hic-5, which localize primarily to focal adhesion plaques. However, in this report, we demonstrate that Trip6 is largely in the nucleus in cells treated with leptomycin B, suggesting that Trip6 shuttles between nuclear and cytoplasmic compartments and that nuclear export of Trip6 is dependent on Crm1. Consistent with this finding, we have identified a nuclear export signal (NES) in Trip6, and mutation of this NES also results in sequestration of Trip6 in the nucleus. Addition of the Trip6 NES to the nuclear v-Rel oncoprotein redirects v-Rel to the cytoplasm. Trip6 also has at least two sequences that can direct cytoplasmic L-galactosidase to the nucleus. Using GAL4 fusion proteins and reporter gene assays, we demonstrate that Trip6 has multiple transactivation domains, including one that appears to overlap with sequences of the NES. In vitro-or in vivo-synthesized Trip6, however, does not bind to DNA^cellulose. Taken together, these results are consistent with Trip6, and other members of this LIM protein family, having a role in relaying signals between focal adhesion plaques and the nucleus. ß
Introduction
LIM domains are thought to be primarily proteinp rotein interaction domains [1, 2] . Trip6 is a LIM domain-containing protein that is part of a subfamily of LIM domain proteins that also includes zyxin, lipoma preferred partner (LPP), Ajuba, paxillin, and Hic-5, among others [1, 2] . These proteins contain three or more copies of highly related LIM domains towards their C-termini.
The exact functions of members of this subfamily of LIM domain proteins are not known. In resting cells, most proteins in this family primarily reside in focal adhesion plaques, but under a variety of circumstances several can also enter the nucleus [3^8]. Moreover, LPP and Trip6 have sequences that can activate transcription [5^7], and Hic-5 can bind DNA through its LIM domain sequences [3] . Zyxin and LPP have been shown to interact with several focal adhesion plaque proteins, including Ena/VASP [5, 9, 10] . In addition, Trip6 has been identi¢ed as interacting with a variety of nuclear (thyroid hormone receptor [11] and v-Rel [7] ) and cytoplasmic (protein phosphatase PTP1E and PTPBL [12, 13] ) proteins. Taken together, these results suggest that these LIM proteins have distinct nuclear and adhesion plaque functions, and may relay signals between focal adhesion plaques and the nucleus.
In this report, we have further investigated the requirements for nuclear activities of Trip6. Our results demonstrate that Trip6 appears to shuttle between cytoplasmic and nuclear compartments, due to a nuclear export signal (NES) towards its N-terminus and nuclear targeting functions in both N-terminal sequences and in C-terminal sequences that include the LIM domains. We also show that Trip6 has multiple transactivation domains, including one that appears to overlap with the NES.
Materials and methods

Recombinant DNA techniques and plasmid constructions
Recombinant DNA techniques were generally performed as described [14] . Site-directed mutagenesis of the NES of Trip6 was performed by PCR using the following oligonucleotides as the mutagenic primers and pcDNA-FLAG-Trip6 [6] as template: 5P-CA-TCAGCCGCCATGCTGGTGGCCGAATCTATC-TC-3P (triple-mutation primer 1) or 5P-GATCAG-CCGCCATGCTGGTGGCCGAATCTATCTC-3P (double-mutation primer 1) or a Trip6-speci¢c primer (for single mutation) and T7 promoter primer to generate 5P NES/mutant PCR product; 5P-AGA-TTCGGCCACCAGCATGGCGGCTGATGCGGA-CGGGGGT-3P (triple-mutation primer 2) or 5P-AG-ATTCGGCCACCAGCATGGCGGCTGATCTGG-ACG-3P (double-mutation primer 2) or 5P-GAT-TCGCTCACCAGCATGTTGGCTGATGCGGAC-GGGGGTCGC-3P (single-mutation primer 2) and a downstream Trip6-speci¢c primer to generate 3P NES/mutant PCR product. After digestion of the NES/mutant PCR products with EcoRI/BstXI and the 3P NES/mutant PCR products with BstXI and SacII, these two fragments were simultaneously subcloned into pcDNA-FLAG-Trip6, which had been digested with EcoRI and SacII.
Retroviral vectors for the expression of v-Rel, v-dStu/Hinc, and TGV have been described previously [15] . To create plasmids v-Rel-NES and v-Rel-NES-mutant, primers were used to amplify the NES-containing region of wild-type and NESmutant Trip6. The fragments were then digested with StuI and HincII, which digested within the de-signed primers, and the fragments were used to replace a 120 bp fragment of v-rel between unique StuI and HincII sites [15] . The recombinant v-rel-trip6/ NES chimeric genes were then subcloned as XbaI fragments into the corresponding site of spleen necrosis virus vector JD214BS+ [16] .
To create a plasmid for the expression of L-galactosidase (L-gal), the lacZ gene with 5P sequences of the CAT gene was digested by HindIII and DraI in plasmid RSV-L-gal [15] , and this fragment was subcloned into HindIII/EcoRV-digested pcDNA3.1(+). To create plasmids expressing the L-gal-LIM and L-gal-vLIM fusion proteins, a C-terminal fragment or the N-terminal region was generated by ScaI/XbaI or HpaI/XbaI digestion of pcDNA-FLAG-Trip6, respectively, and these fragments were then ligated to lacZ (in-frame) in pcDNA3.1-L-gal that had been treated with BlpI/Klenow and XbaI. To create pcDNA3.1-L-gal-vLIM/NES mutant, the KpnI/ BspEI fragment from pcDNA3-Trip6/NES mutant was subcloned into pcDNA3.1-L-gal treated by KpnI/BspEI. All subclones were con¢rmed by DNA sequencing and in vitro translation.
The GAL4 producer plasmid SG424 and GAL4T rip6 producer plasmid SG-MoTrip6 (GAL4-vN-Trip6-1) have been described previously [6, 17] . pcDNA-FLAG-Trip6-LIM and pcDNA-FLAG-Trip6-vLIM were produced by EcoRI/Klenow and ScaI or NotI/Klenow and ScaI digestion of pcDNA-FLAG-Trip6, respectively, and the vector backbones were then religated. GAL4^Trip6, GAL4^Trip6-LIM and GAL4^Trip6-vLIM were then created by subcloning HpaI and XbaI fragments from corresponding pcDNA-FLAG plasmids (described above) into pSG424 that had been treated with KpnI/T4-DNA-polymerase and XbaI. GAL4-vN-Trip6-2 was made by subcloning an EcoRI/Klenow-and XbaI-treated fragment from pcDNA-FLAG-vN-Trip6 [6] into pSG424 that had been treated with BamHI/Klenow and XbaI. To create pcDNA-FLAG-vN-Trip6-3, an NcoI/Klenow-treated to NotI fragment of a mouse Trip6 cDNA was subcloned into pcDNA-FLAG that had been digested with BamHI, treated with Klenow and then digested with NotI. GAL4-vN-Trip6-3 was then made by subcloning a BamHI/XbaI-digested fragment from pcDNA-FLAG-vN-Trip6-3 into the corresponding sites of pSG424. All pSG-Trip6/NES-mutants were created by subcloning KpnI/XbaI fragments from the given pcDNA-Trip6/NES mutants into pSG-Trip6 that had been digested with KpnI and XbaI. Plasmid SG-zyxin was created by subcloning a fragment containing codons 1^572 of human zyxin into pSG424 that had been treated with KpnI/Klenow/XbaI. All subclones that involved blunt-end ligations were con-¢rmed by DNA sequencing.
Cell culture, GAL4-site reporter gene assays, and indirect immuno£uorescence
Chicken embryo ¢broblasts (CEF) were obtained from Spafas, Inc. and were cultured in Dulbecco's modi¢ed Eagle's medium containing 10% fetal calf serum. Where indicated, leptomycin B (a kind gift of Minoru Yoshida) was added at 20 ng/ml. GAL4-site CAT reporter gene assays were performed as described previously [6] . Indirect immuno£uorescence on transfected cells was performed by ¢xing cells in paraformaldehyde and using primary antiserum against FLAG, L-gal, or GAL4 as described previously [6, 15, 18] . Detection of antigens with £uorescein-conjugated secondary antibody and DAPI staining were also performed as described previously [6] .
DNA-binding assays
Coupled in vitro transcription/translation was performed in wheat germ extract or rabbit reticulocyte lysate in the presence of Tran 35 S-label (Amersham) according to the manufacturer's (Promega) recommendations as described previously [6] . FLAG epitope-tagged full-length Trip6 and N-terminally truncated Trip6(vN) were translated in vitro from pcDNA-FLAG-Trip6 and pcDNA-FLAG-vN-Trip6, respectively. Trip6, c-Src, v-Rel and v-Rel mutant (v-dStu/Hinc) were translated in vitro from pGEM4-MoTrip6, pGEM4-c-Src, CG129 and CG129/dStu/Hinc expression plasmids, respectively, which have been described previously [6, 19] . Double-stranded DNA^cellulose (USB Corporation; 80 mg/ml) was preincubated in BD bu¡er (0.2 M NaCl, 50 mM Tris, pH 7.5, 0.2 mM ZnCl 2 , 0.2% (v/v) Triton X-100, 5% (v/v) glycerol, 2 mg/ml BSA) at 4³C overnight, and 50 Wl DNA^cellulose was then incubated with 5^10 Wl of in vitro-translated proteins in BD bu¡er at room temperature for 2 h, washed once with BD bu¡er brie£y, twice with wash bu¡er (0.3 M NaCl, 50 mM Tris, pH 7.5, 0.2 mM ZnCl 2 , 1% Triton X-100, 0.1% SDS, 5% glycerol) for 10 min each at room temperature. DNA^cellulose beads were pelleted and boiled in 2USDS sample bu¡er (0.125 M Tris, pH 6.8, 4.6% SDS, 20% glycerol, 10% L-mercaptoethanol, 0.2% bromophenol blue) at 95^100³C for 20 min. The supernatant was then loaded on a 12.5% SDS-polyacrylamide gel, and proteins were detected using a Molecular imager (Bio-Rad). Two microliters of in vitro-translated proteins were loaded on a parallel gel as a control. The generation of chicken spleen cells transformed by retroviral vector pMH-v-Rel-IRES-FLAG-vN-Trip6 has been described previously [7] . Eight milliliters of an exponentially growing culture of these suspension cells were pelleted and cells were then incubated in 150 Wl of lysis bu¡er (0.2 M NaCl, 50 mM Tris, pH 7.5, 0.2 mM ZnCl 2 , 0.5% NP-40, 0.5 mM DTT, 10% glycerol, 1% aprotinin (Sigma), 2 Wg/ml leupeptin (Sigma)) on ice for 40 min. Samples were pelleted at top speed in a microcentrifuge for 10 min at 4³C, and the supernatant was then repelleted for 20 min at 4³C. 120 Wl of supernatant was incubated with BD bu¡er containing DNA^cellulose, and beads were washed as described above. Samples were then boiled in 2USDS sample bu¡er and resolved on 12.5% SDS-polyacrylamide gels. Fifteen microliters of cell lysate supernatant (described above) was loaded on the gel in parallel as a control. Western blotting was then performed using either anti-Rel or anti-FLAG antiserum as a primary antibody as described previously [6] .
Results
Treatment of cells with leptomycin B causes
Trip6 to accumulate in the nucleus
The Trip6-related proteins zyxin and LPP have been shown to shuttle between focal adhesion plaques and the nucleus [4, 5] . For this reason, we were interested in determining whether Trip6, which is primarily located in adhesion plaques when overexpressed in CEF [6] , also shuttles between cytoplasmic and nuclear compartments. Therefore, CEF transfected with a FLAG-Trip6 expression vector were treated with leptomycin B, which is an inhibitor of Crm1-dependent nuclear export [20, 21] . The subcellular localization of FLAG-Trip6 was then analyzed by indirect immuno£uorescence using an anti-FLAG primary antibody. Consistent with our previous results [6, 7] , over-expressed FLAG-Trip6 in untreated CEF resides primarily in focal adhesion plaques ( Fig. 1A ). However, upon treatment of cells with leptomycin B for as short as 15 min or as long as 4 h, the majority of FLAG-Trip6 was localized in the nucleus (Fig. 1B,C) . These results suggest that Trip6 shuttles between cytoplasmic and nuclear compartments, and that the movement of Trip6 from the nucleus to the cytoplasm is dependent on Crm1, as it is blocked speci¢cally by leptomycin B.
Trip6 contains a conserved NES between residues 100 and 107
We have previously shown that deletion of the Nterminal 115 aa of mouse Trip6 causes it to accumulate in the nucleus [6, 7] , suggesting that these sequences contain a NES. Therefore, we used three approaches to identify the Trip6 NES. First, deletion analysis indicated that the Trip6 NES was located between residues 72 and 115 of mouse Trip6, in that deletion of these sequences caused nuclear accumulation of Trip6 ( Fig. 2A) . Second, inspection of these sequences identi¢ed a leucine-rich sequence (Fig. 2B) , which is characteristic of Crm1-dependent NESs. Third, conversion of the leucine residues within this putative NES to alanine residues caused FLAG-Trip6 to accumulate in the nucleus (Fig. 2C ).
If these sequences in Trip6 were an independent NES, we reasoned that they should be able to export a heterologous protein from the nucleus. For these experiments we used a mutant of the v-Rel oncoprotein (v-dStu/Hinc), which is primarily located in the nucleus of CEF (Fig. 2D , panel v-dStu/Hinc) [15] . (This deletion mutant of v-Rel was used since it can conveniently accommodate insertions in the middle portion of the protein and it does not interact with cellular proteins that might a¡ect localization of v-Rel [15] .) Insertion of Trip6 aa 76 to 115 in the middle of the v-dStu/Hinc mutant caused this v-Rel protein to localize primarily to the cytoplasm ( Fig. 2D, panel WT) . In contrast, addition of the same Trip6 sequences containing the mutant NES or addition of sequences from control protein (Lgal) did not a¡ect the primarily nuclear localization of v-dStu-Hinc (Fig. 2D , panels Mut and TGV).
Taken together, the results in this section indicate that Trip6 has a leucine-rich NES. Notably, this leucine-rich sequence is conserved in the related proteins zyxin, LPP and Ajuba (Fig. 2E ).
The N-and C-terminal regions of Trip6 have nuclear targeting functions that can enhance nuclear accumulation of L-gal
Because Trip6 can enter the nucleus after treatment with leptomycin B and has an NES, we suspected that Trip6 also had sequences that could direct it to the nucleus. To determine whether Trip6 has a nuclear targeting function, we fused either the N-or C-terminal halves of Trip6 to L-gal and monitored the subcellular localization of the proteins by indirect immuno£uorescence using an anti-L-gal primary antibody. L-gal by itself is evenly distributed between the cytoplasm and the nucleus in CEF (Fig. 3 , panel L-gal). Fusion of the C-terminal half (aa 280^480) of Trip6 to the C-terminus of L-gal resulted in a L-gal fusion protein that was located in the nucleus (Fig. 3 , panel L-gal-LIM). This result indicates that Trip6 aa 280^480, which contain the three LIM domains, contain a sequence capable of targeting a heterologous protein to the nucleus.
We also fused sequences in the N-terminal half of Trip6 (aa 2^282) to the C-terminus of L-gal. This protein was located exclusively in the cytoplasm (Fig. 3 , panel L-gal-vLIM), consistent with it containing a functional NES as determined above (see Fig. 2 ). However, if these N-terminal Trip6 sequences contained a mutated and non-functional NES, the L-gal fusion protein was now located in the nucleus. This indicates that the N-terminal region of Trip6 also contains a nuclear targeting sequence, whose activity is evident only upon disabling of the NES.
Trip6 has multiple transactivation domains
We have previously shown that C-terminal sequences of mouse or human Trip6, including the LIM domains, can activate transcription in yeast and CEF when fused to the GAL4 DNA-binding domain [6, 7] . As shown in Fig. 4A , GAL4 fusion proteins containing either full-length Trip6 or the related protein zyxin can also readily activate transcription in CEF. To map the sequences in Trip6 responsible for (E) Indirect immuno£uorescence using an anti-GAL4 primary antibody of CEF transfected with expression vectors for the indicated proteins. Fig. 4 (continued) transcription activation, we performed GAL4-site CAT reporter gene assays in CEF with a series of GAL4^Trip6 fusion proteins (Fig. 4B ). This analysis shows that sequences from both the N-and C-terminal halves of Trip6 contribute to its transactivation ability. The deletion mutants indicate that Trip6 contains one transactivation domain in the C-terminal LIM domain region (aa 280^480) and a second transactivation domain between residues 72 and 115.
Because the N-terminal transactivation region (aa 72^115) in Trip6 also contains the NES, we wished to determine whether the NES was functionally distinct from the transactivation activity. Therefore, we assayed the ability of the Trip6 NES Leu-to-Ala triple mutant to activate transcription. As shown in Fig. 4C , mutation of all Leu residues within the NES greatly reduced the ability of GAL4^Trip6 fusion proteins to activate transcription (compare fulllength and vN mutants with the corresponding wildtype Trip6 proteins, Fig. 4C ). In addition, single or double Leu-to-Ala mutations within the NES resulted in both nuclear accumulation and reduced transactivation (Fig. 4D) .
Because the NES mutations altered a function involved in subcellular localization, we were interested in comparing the subcellular localization of wild-type and NES mutant GAL4^Trip6 proteins. Wild-type GAL4^Trip6 shows a primarily cytoplasmic staining pattern, whereas the NES mutant GAL4^Trip6 protein is primarily in the nucleus (Fig. 4E) . Thus, wild-type GAL4^Trip6 activates transactivation more strongly than NES mutant GAL4^Trip6 proteins even though there is less wild-type GAL4^Trip6 protein in the nucleus. Taken together, the results in this section demonstrate that the same Leu-to-Ala mutations that alter the Trip6 NES function reduce transactivation, suggesting that the NES and transactivation sequences of Trip6 within aa 72 and 115 overlap.
Trip6 does not bind to DNA^cellulose in vitro
Because of the nuclear functions of Trip6 and the fact that LIM domains are often associated with DNA-binding proteins [7, 9, 11] we next determined whether Trip6 could bind DNA. In these experiments, in vitro-translated Trip6 or Trip6 isolated from v-Rel-transformed spleen cells was analyzed for its ability to bind to DNA^cellulose. Because the binding of the related LIM domain protein Hic-5 is dependent on zinc [3] , zinc was included in all experiments. As shown in Fig. 5A , in vitro-translated full-length Trip6 or vN-Trip6 (aa 116^480 of Trip6) did not bind to DNA^cellulose. As controls in these experiments, the v-Rel transcription factor did bind to DNA (last lane in right panel of Fig. 5A ), but a v-Rel mutant (v-dStu/Hinc, see Fig. 2D ) that cannot bind to UB sites and the plasma membrane protein c-Src did not bind to DNA (Fig. 5A right  panel) . Similarly, when isolated from v-Rel-transformed spleen cells, FLAG-vNTrip6 did not bind Fig. 4 (continued) to DNA, whereas v-Rel did (Fig. 5B) . These results indicate that, at least under the conditions used here, neither full-length Trip6 nor the LIM domain region of Trip6 can bind to DNA^cellulose.
Discussion
In this report, we provide extensive evidence that LIM domain protein Trip6 shuttles between focal adhesion plaques and the nucleus. That is, treatment of cells with leptomycin B, an inhibitor of Crm1-dependent nuclear export, results in nuclear accumulation of Trip6, and Trip6 has an independent NES. In addition, N-and C-terminal sequences of Trip6, including the LIM domains, have a nuclear targeting signal. Moreover, we show that Trip6 has multiple transactivation domains, and that mutations that abolish the NES function also lessen transactivation by Trip6.
Although Trip6 and the related proteins zyxin and LPP have all been shown to shuttle between focal adhesion plaques and the nucleus, these proteins appear to largely reside in adhesion plaques in the steady-state [5^7,9] . For example, at any given moment, very little Trip6 appears in the nucleus in control cells overexpressing Trip6 (see Fig. 1A ). Nevertheless, treatment of CEF with leptomycin B for as little as 15 min results in an almost exclusively nuclear localization of Trip6. One interpretation of these results is that Trip6 is very rapidly exported from the nucleus once it enters it. Alternatively, the focal adhesion plaque localization of Trip6 is dependent on a leptomycin B sensitive function or protein, which, when inhibited, causes Trip6 to rapidly enter the nucleus.
Our results identify the Trip6 NES as being part of a leucine-rich sequence from aa 100 to 107, which is analogous to the NESs that were identi¢ed in LPP and Ajuba [5, 8] . Curiously, a di¡erent leucine-rich sequence was identi¢ed as an NES in the highly related protein zyxin [4] , even though both leucine-rich sequences are highly related in Trip6, LPP and zyxin [6] . Our identi¢cation of the Trip6 NES is unambiguous: that is, deletion or mutation of this sequence sequesters Trip6 in the nucleus and this NES can independently export a heterologous protein (v-Rel) from the nucleus (Fig. 2) . Moreover, deletion of the zyxin-like NES from Trip6 does not alter its focal adhesion plaques localization (Wang and Gilmore, unpublished results). Thus, the reason for the di¡erence in function of these leucine-rich NESs between Trip6 and LPP versus zyxin is not clear.
We have also shown that sequences of Trip6, including the LIM domains, can direct cytoplasmic L-gal to the nucleus. Inspection of the Trip6 sequences reveals no obvious consensus (basic) nuclear targeting sequence [22] . Thus, either Trip6 has an unconventional nuclear localization sequence or, for example, the LIM domains interact with a protein that brings these sequences to the nucleus. Of note, armadillo repeat domains, also protein^protein interaction domains, have been shown to participate directly in nuclear localization of L-catenin [23, 24] and possibly the APC tumor suppressor protein [25] .
Our results have also identi¢ed (at least) two transactivation domains in Trip6: one between aa 72 and 115 and one including the C-terminal LIM domains. The transactivation domain between 72 and 115 appears to overlap with the Trip6 NES in that Leu-to-Ala mutations that abolish the nuclear export function also greatly lessen the transactivation function. Alternatively, nuclear export of Trip6 is required for a nearby transactivation domain to function maximally. In either case, to our knowledge, this is the ¢rst identi¢cation of an NES that is part of or required for a transactivation domain.
It is still not clear what relevance nuclear localization or transactivation has for the function of Trip6. In that we have shown that Trip6 does not bind to DNA^cellulose (Fig. 5 ), it appears unlikely that Trip6 functions as a direct activator of transcription.
We have previously shown that a nuclear-localized form of Trip6 can act as a co-activator for the v-Rel transcription factor [7] . In addition, Trip6 can interact with thyroid hormone receptor, a nuclear localized sterol receptor, in a hormone-dependent manner [11] . Of note, JAB1, which was originally identi¢ed as a co-activator of the c-Jun transcription factor, is co-localized with integrin LFA-1 at the cell membrane, but upon activation of LFA-1 a fraction of JAB1 enters the nucleus [26] .
However, no cellular signal has been identi¢ed that can induce nuclear localization of Trip6, nor the related proteins zyxin, LPP, or Ajuba. For example, activation of focal adhesion kinase (FAK) by v-Src does not induce nuclear translocation of Trip6 nor does treatment of cells with cytochalasin D, an actin ¢lament disrupting reagent, or okadaic acid, a Ser/ Thr phosphatase inhibitor, induce its nuclear translocation (Wang and Gilmore, unpublished results).
Although zyxin, Trip6, LPP, Ajuba, and Hic-5 are highly related LIM domain proteins, which largely reside in adhesion plaques but can enter the nucleus and can activate transcription, these proteins clearly have di¡erences. For example, although Ajuba can enter the nucleus, it appears to be largely cytosolic [8] rather than localized in adhesion plaques like other members of this family. Similarly, although Hic-5 has been shown to bind to DNA [3] , the other members of this family have not. As described above, the sequences that act as NESs for zyxin and Trip6 may di¡er. Furthermore, although zyxin and LPP have been shown to bind to the VASP/Ena protein [5, 10] , which is likely to be involved in the regulation of cell migration [27] , Trip6 does not appear to have a VASP-Ena binding domain. Lastly, nuclear-localized Ajuba and Trip6 proteins can promote embryonic carcinoma cell di¡erentiation, but zyxin cannot [8] . Taken together, these results indicate that these related LIM domain proteins have distinct functions. It will be of interest to determine the e¡ect of disruption of the genes encoding these proteins in mice and the e¡ect of their overexpression in tissue culture cells.
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